-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
Spotlight on the WCLC 2025 Talent Showcase
Prepare to be amazed as members of the global lung cancer community take center stage in Barcelona.
-
A Pragmatic Approach to Trial Design
Although the primary finding was not what investigators had hoped for, recent presentations by Drs. Karen Reckamp and Konstantin H. Dragnev highlighted Pragmatica-Lung’s success as a model for future trials.
-
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC
Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment.
-
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC
The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations.
-
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher.
-
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer.
-
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC
Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting.
-
Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC
Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery.
-
Overcoming Resistance Remains a Challenge in Targeting KRAS
Dana-Farber’s Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space.
-
Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy
Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC.